Stay updated on Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Sign up to get notified when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.

Latest updates to the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page
- Check4 days agoChange DetectedAdded a Locations section listing Michigan, Utah, Washington, and Wisconsin. Removed the separate Michigan, Utah, Washington, and Wisconsin Locations sections and the HHS Vulnerability Disclosure link; updated the page to revision v3.3.3.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedPublication notes now say that publications are automatically filled from PubMed and may or may not be about the study. The Revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the banner about government funding lapse and NIH operating status from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check61 days agoChange DetectedNo additions or deletions detected; the page content remains unchanged.SummaryDifference0.4%

- Check83 days agoChange Detected- Added a government-operating-status notice and a link to official sources; - Updated software version from v3.1.0 to v3.2.0; - Removed the old version reference.SummaryDifference3%

- Check90 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release. No other content changes were detected.SummaryDifference0.1%

Stay in the know with updates to Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.